logo

Aveo Pharmaceuticals, Inc. (AVEO)



Trade AVEO now with
  Date
  Headline
2/22/2022 8:06:29 AM Actinium Pharma, AVEO Oncology To Develop First-in-Class Actinium-225 ErbB3 Targeting Radiotherapy For Solid Tumors
12/1/2021 7:10:43 AM AVEO Oncology Appoints Jeb Ledell As COO
9/20/2021 7:05:26 AM AVEO Oncology Says US FDA Grants Fast Track Designation To Ficlatuzumab For R/R Head And Neck Squamous Cell Carcinoma
4/16/2021 7:03:32 AM AVEO Oncology Appoints Kevin Cullen To Board
3/23/2021 10:38:13 PM AVEO Oncology Prices Public Offering Of 6 Mln Shares At $8.00/shr
3/22/2021 4:10:42 PM AVEO Announces Proposed Public Offering Of Common Stock
3/22/2021 7:15:07 AM AVEO Oncology Announces U.S. Commercial Availability Of FOTIVDA For Relapsed Or Refractory Advanced Renal Cell Carcinoma
3/15/2021 7:03:33 AM AVEO Oncology To Regain Its Rights To AV-203 Outside Of North America
3/12/2021 7:06:19 AM AVEO Collaborates With BMY To Evaluate FOTIVDA-OPDIVO In Phase 3 TiNivo-2 Trial In IO Relapsed Renal Cell Carcinoma
1/20/2021 7:07:39 AM AVEO Oncology Announces Commitment For Incremental $10 Mln Loan In Addition To Current Tranched
1/15/2021 8:18:56 AM AVEO Oncology Announces Results From Phase 1b Portion Of DEDUCTIVE Study Of Tivozanib In Combination With IMFINZI
1/7/2021 7:29:55 AM AVEO Oncology Highlights Recent Progress And Outlines 2021 Outlook
11/13/2017 10:07:53 AM B. Riley FBR Initiates AVEO Pharmaceuticals, Inc. (AVEO) At Buy With $5 Price Target
3/30/2016 8:30:46 AM FBR Capital Markets Initiates AVEO Pharmaceuticals, Inc. (AVEO) At Outperform With $3 Price Target
5/8/2014 1:36:55 PM RBC Capital Markets Is Increasing AVEO Pharmaceuticals, Inc. (AVEO) FY 14 Rev. Estimate To 16.0 M From 1.0 M
5/8/2014 1:36:09 PM RBC Capital Markets Is Cutting AVEO Pharmaceuticals, Inc. (AVEO) 3Q14 Estimate To -0.24 From -0.21
5/8/2014 1:35:47 PM RBC Capital Markets Is Lowering AVEO Pharmaceuticals, Inc. (AVEO) 2Q14 Estimate To -0.29 From -0.26